Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3981MR)

This product GTTS-WQ3981MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3981MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14962MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ5861MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5690MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ14393MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ13160MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ10468MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ13810MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ88MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 1121B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW